These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1003240)

  • 1. Dopamine correlates of neurological and psychological status in untreated Parkinsonism.
    Hoehn MM; Crowley TJ; Rutledge CO
    J Neurol Neurosurg Psychiatry; 1976 Oct; 39(10):941-51. PubMed ID: 1003240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased dopamine in the retinas of patients with Parkinson's disease.
    Harnois C; Di Paolo T
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2473-5. PubMed ID: 2243012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
    Bronaugh RL; MacMurtry RJ; Hoehn MM; Rutledge CO
    Biochem Pharmacol; 1975 Jul; 24(13-14):1317-20. PubMed ID: 1096899
    [No Abstract]   [Full Text] [Related]  

  • 4. The Parkinsonian syndrome and its dopamine correlates.
    Hoehn MM; Crowley TJ; Rutledge CO
    Adv Exp Med Biol; 1977; 90():243-54. PubMed ID: 930745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of endogenous dopamine metabolism in Gilles de la Tourette's disease.
    Messiha FS; Knopp W
    Dis Nerv Syst; 1976 Aug; 37(8):470-3. PubMed ID: 1066216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F; Rosa A; Comoy E
    Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Catecholamine metabolism in different forms of Parkinson's disease].
    Selikhova MV; Kogan BM; Serkin GV; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):37-40. PubMed ID: 12378880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
    Melamed E; Globus M; Rosenthal J; Uzzan A
    Adv Neurol; 1987; 45():507-10. PubMed ID: 3825730
    [No Abstract]   [Full Text] [Related]  

  • 11. Does levodopa alter depression and psychopathology in Parkinsonism patients?
    Marsh GG; Markham CH
    J Neurol Neurosurg Psychiatry; 1973 Dec; 36(6):925-35. PubMed ID: 4149286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
    Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL; Chalmers RJ; Johnson RH
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
    Markianos M; Hadjikonstantinou M
    Eur Neurol; 1981; 20(2):118-24. PubMed ID: 6260505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary Parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication.
    Allen N; Knopp W
    Adv Neurol; 1976; 14():201-13. PubMed ID: 942621
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical pharmacokinetics of levodopa in parkinson's disease.
    Bianchine JR; Shaw GM
    Clin Pharmacokinet; 1976; 1(5):313-38. PubMed ID: 797502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
    Korf J; van Praagen HM; Lakke JP
    Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathobiochemical implications of hyperdopaminuria in patients with aromatic L-amino acid decarboxylase deficiency.
    Abeling NG; Bräutigam C; Hoffmann GF; Barth PG; Wevers RA; Jaeken J; Fiumara A; Knust A; van Gennip AH
    J Inherit Metab Dis; 2000 Jun; 23(4):325-8. PubMed ID: 10896285
    [No Abstract]   [Full Text] [Related]  

  • 20. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.